BR0115208A - Tratamento aperfeiçoado - Google Patents
Tratamento aperfeiçoadoInfo
- Publication number
- BR0115208A BR0115208A BR0115208-4A BR0115208A BR0115208A BR 0115208 A BR0115208 A BR 0115208A BR 0115208 A BR0115208 A BR 0115208A BR 0115208 A BR0115208 A BR 0115208A
- Authority
- BR
- Brazil
- Prior art keywords
- iop
- agents
- enhanced treatment
- susceptible
- therapy
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 206010047571 Visual impairment Diseases 0.000 abstract 1
- 230000006735 deficit Effects 0.000 abstract 1
- 230000004410 intraocular pressure Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 208000029257 vision disease Diseases 0.000 abstract 1
- 230000004393 visual impairment Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Glass Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
"TRATAMENTO APERFEIçOADO". A presente invenção está direcionada à utilização de dois ou mais agentes em combinação com capacidade de redução da pressão intra-ocular (IOP) em uma terapia com uma eficácia aperfeiçoada para tratar glaucoma avançado em tais pacientes que sofrem a partir de prejuízos relacionados à visão detectáveis, quando referidos agentes são administrados simultaneamente. A utilização combinada irá também encontrar vantagem em tratamento de indivíduos em necessidade de uma alta redução de IOP, tais como aqueles sendo expostos aos fatores de risco provocando neles susceptibilidade para prejuízos visuais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24812300P | 2000-11-13 | 2000-11-13 | |
PCT/SE2001/002499 WO2002038158A1 (en) | 2000-11-13 | 2001-11-12 | Improved treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0115208A true BR0115208A (pt) | 2003-10-07 |
Family
ID=22937766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0115208-4A BR0115208A (pt) | 2000-11-13 | 2001-11-12 | Tratamento aperfeiçoado |
Country Status (17)
Country | Link |
---|---|
US (1) | US20030018079A1 (pt) |
EP (1) | EP1333837A1 (pt) |
JP (1) | JP2004513148A (pt) |
KR (1) | KR20030068150A (pt) |
CN (1) | CN1233324C (pt) |
AR (1) | AR035541A1 (pt) |
AU (1) | AU2002215277A1 (pt) |
BR (1) | BR0115208A (pt) |
CA (1) | CA2426049A1 (pt) |
EA (1) | EA200300560A1 (pt) |
HU (1) | HUP0400548A3 (pt) |
MX (1) | MXPA03004183A (pt) |
NO (1) | NO20032122L (pt) |
NZ (1) | NZ525817A (pt) |
PL (1) | PL362855A1 (pt) |
WO (1) | WO2002038158A1 (pt) |
ZA (1) | ZA200303771B (pt) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI298257B (en) | 2001-05-31 | 2008-07-01 | Allergan Inc | Hypotensive lipid and timolol compositions and methods of using same |
WO2003078662A1 (en) * | 2002-03-13 | 2003-09-25 | Genomic Health | Gene expression profiling in biopsied tumor tissues |
JP2005526092A (ja) * | 2002-03-21 | 2005-09-02 | ケイマン ケミカル カムパニー | 緑内障および眼圧亢進を治療するためのプロスタグランジンF2α類縁体およびそれらの抗菌タンパク質との併用法 |
KR101092048B1 (ko) | 2002-08-29 | 2011-12-12 | 산텐 세이야꾸 가부시키가이샤 | Rho 키나아제 억제제 및 프로스타글란딘류를 포함하는녹내장 치료제 |
US7074827B2 (en) * | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
JP4314433B2 (ja) * | 2002-11-18 | 2009-08-19 | 参天製薬株式会社 | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 |
EP1663230A1 (en) * | 2003-09-05 | 2006-06-07 | Novartis AG | Compositions comprising benzo(g)quinoline derivatives and prostaglandin derivatives |
ME02433B (me) | 2004-01-05 | 2016-09-20 | Nicox Sa | Nitrooksiderivati prostaglandina |
SI1759702T1 (sl) | 2004-05-26 | 2009-06-30 | Bayardo Arturo Jimenez | Postopek pripravljanja oftalmiäśne raztopine latanoprosta in tako proizvedena raztopina |
GB0501192D0 (en) * | 2005-01-20 | 2005-03-02 | Resolution Chemicals Ltd | Stable prostaglandin-containing compositions |
KR101326425B1 (ko) | 2005-06-21 | 2013-11-11 | 코와 가부시키가이샤 | 녹내장의 예방 또는 치료제 |
US8193193B2 (en) | 2005-07-12 | 2012-06-05 | Kowa Co., Ltd. | Agent for prevention or treatment of glaucoma |
ITRM20080182A1 (it) * | 2008-04-07 | 2009-10-08 | Medivis S R L | Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma. |
WO2010119305A1 (en) * | 2009-04-14 | 2010-10-21 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Using of quaternary ammonium compounds in dissolving of latanoprost |
CN102085175B (zh) * | 2009-12-02 | 2013-01-30 | 沈阳兴齐眼药股份有限公司 | 一种眼用凝胶剂及其制备方法 |
FR2961694B1 (fr) * | 2010-06-29 | 2013-01-25 | Thea Lab | Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur |
US9061034B2 (en) | 2010-07-29 | 2015-06-23 | Allergan, Inc. | Preservative free bimatoprost and timolol solutions |
JP6023082B2 (ja) * | 2011-01-24 | 2016-11-09 | インセプタム リサーチ アンド セラピューティクス,インク. | 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物 |
WO2012105674A1 (ja) | 2011-02-04 | 2012-08-09 | 興和株式会社 | 緑内障予防又は治療のための薬物療法 |
CN102389433A (zh) * | 2011-11-04 | 2012-03-28 | 兆科药业(香港)有限公司 | 一种药物组合物及其复方制剂 |
CN111479568A (zh) | 2017-12-21 | 2020-07-31 | 参天制药株式会社 | 司培前列素与Rho激酶抑制剂的组合药物 |
TW201927303A (zh) | 2017-12-21 | 2019-07-16 | 日商參天製藥股份有限公司 | 歐米德尼培(Omidenepag)之組合 |
-
2001
- 2001-11-09 AR ARP010105259A patent/AR035541A1/es not_active Application Discontinuation
- 2001-11-09 US US10/035,963 patent/US20030018079A1/en not_active Abandoned
- 2001-11-12 CN CNB018185924A patent/CN1233324C/zh not_active Expired - Fee Related
- 2001-11-12 KR KR10-2003-7006437A patent/KR20030068150A/ko not_active Application Discontinuation
- 2001-11-12 EP EP01983882A patent/EP1333837A1/en not_active Withdrawn
- 2001-11-12 AU AU2002215277A patent/AU2002215277A1/en not_active Abandoned
- 2001-11-12 PL PL01362855A patent/PL362855A1/xx unknown
- 2001-11-12 EA EA200300560A patent/EA200300560A1/ru unknown
- 2001-11-12 CA CA002426049A patent/CA2426049A1/en not_active Abandoned
- 2001-11-12 JP JP2002540741A patent/JP2004513148A/ja not_active Withdrawn
- 2001-11-12 HU HU0400548A patent/HUP0400548A3/hu unknown
- 2001-11-12 NZ NZ525817A patent/NZ525817A/en unknown
- 2001-11-12 WO PCT/SE2001/002499 patent/WO2002038158A1/en not_active Application Discontinuation
- 2001-11-12 MX MXPA03004183A patent/MXPA03004183A/es unknown
- 2001-11-12 BR BR0115208-4A patent/BR0115208A/pt not_active IP Right Cessation
-
2003
- 2003-05-12 NO NO20032122A patent/NO20032122L/no unknown
- 2003-05-15 ZA ZA200303771A patent/ZA200303771B/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUP0400548A3 (en) | 2007-05-29 |
ZA200303771B (en) | 2004-05-17 |
EA200300560A1 (ru) | 2003-10-30 |
WO2002038158A8 (en) | 2003-01-30 |
NO20032122D0 (no) | 2003-05-12 |
CN1473046A (zh) | 2004-02-04 |
WO2002038158A1 (en) | 2002-05-16 |
AR035541A1 (es) | 2004-06-16 |
JP2004513148A (ja) | 2004-04-30 |
HUP0400548A2 (hu) | 2004-06-28 |
KR20030068150A (ko) | 2003-08-19 |
NZ525817A (en) | 2005-03-24 |
PL362855A1 (en) | 2004-11-02 |
CA2426049A1 (en) | 2002-05-16 |
EP1333837A1 (en) | 2003-08-13 |
MXPA03004183A (es) | 2004-12-02 |
AU2002215277A1 (en) | 2002-05-21 |
CN1233324C (zh) | 2005-12-28 |
US20030018079A1 (en) | 2003-01-23 |
NO20032122L (no) | 2003-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0115208A (pt) | Tratamento aperfeiçoado | |
BR0213975A (pt) | Métodos para tratar doenças neovasculares oculares | |
BR0107705A (pt) | Uso de uma alìquota de sangue modificado em um paciente para tratamento de falência cardìaca congestiva | |
PT868186E (pt) | Utilizacao de certos compostos de isoquinolinossulfonilo para tratamento de glaucoma e isquemia ocular | |
WO2004004757A8 (en) | Treatment for eye disorder | |
BRPI0415249A (pt) | terapia de combinação para infecção por hcv | |
BR0111591A (pt) | Compostos, composição farmacêutica, e, métodos para elevar o nìvel de plasma do hormÈnio de crescimento em um mamìfero, para o tratamento de deficiência da secreção do hormÈnio de crescimento, para o tratamento do retardo do crescimento em crianças, para o tratamento de distúrbios metabólicos associados com a deficiência da secreção do hormÈnio de crescimento, em particular em pacientes idosos, e para promover a cura de ferimentos, recupeção de cirurgia ou recuperação de doenças debilitantes | |
Leung et al. | Pressure treatment for hypertrophic scars resulting from burns | |
Lipsker et al. | Chloroquine-quinacrine association in resistant cutaneous lupus | |
BR0210013A (pt) | Gel oftálmico de pirenzepina | |
WO1998026770A3 (en) | The topical use of kappa opioid agonists to treat ocular pain | |
BR0016918A (pt) | Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas | |
BR0109753A (pt) | Combinação farmacêutica, formulação farmacêutica, conjunto de partes, método para tratamento profilático ou terapêutico de um paciente que sofre de, ou é suscetìvel a, aterosclerose, e, usos de uma formulação, de uma combinação, ou de um conjunto de partes | |
BG101803A (en) | Use of melatonin for treating patients suffering from drug addiction | |
EP1037622A4 (en) | TAURIN DERIVATIVES FOR THE TREATMENT OF OPHTHALMIC DISORDERS | |
Quirk et al. | Treatment of nonoccupational limb and trunk dystonia with botulinum toxin | |
AU1601499A (en) | Citicoline to treat motor neuron diseases and demyelinating diseases | |
Diao et al. | [Retracted] Clinical Observation of Alternative Wave Electroacupuncture Combined with Lee’s Naprapathy in Treating Knee Osteoarthritis (Blood Stasis due to Qi Stagnation) | |
KR20010089975A (ko) | 캡사이신을 이용한 만성 전립선염, 전립선 비대증, 치질및 발기부전 치료제 | |
UA40487A (uk) | Спосіб хірургічного лікування хворих з сторонніми тілами, локалізованими в "пограничній зоні" ока, та відшаруванням сітківки | |
Makashova | INFLUENCE OF MEDICAL THERAPY ON VISUAL FUNCTIONS HYDRODYNAMICS AND BLOOD-FLOW IN THE OPTIC NERVE IN PATIENTS WITH GLAUCOMA IN COMBINATION WITH MYOPIA | |
RU2002109353A (ru) | Способ лимфотропной терапии больных открытоугольной глаукомой с нормализованным внутриглазным давлением | |
YOSHIKAWA et al. | Effect on Intensive Pleoptics of Eccentric Fixation | |
James | Major study shows AZT monotherapy inferior | |
刘宝华 et al. | TREATMENT OF ONE CASE OF SEVERE APHASIA WITH COMBINED THERAPIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A , 7A E 8A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2021 DE 29/09/2009. |